Alector’s 71% drop prompts a fresh look at its valuation, financials, and pipeline to gauge recovery prospects amid lingering ...

A team of researchers from the University of Maryland School of Medicine (UMSOM) recently won a $250,000 prize from the ...

Recent advances in glucose management are reshaping our understanding of cognitive decline and dementia prevention. Energy ...

Japanese drugmaker JCR Pharmaceuticals has entered into a joint collaboration, option and license agreement with US biotech Acumen Pharmaceuticals to develop a novel therapeutic candidate for the ...

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...

A stem-cell-based "organ-on-a-chip" model of ALS mimics early biological changes seen in the degenerative disease.

For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of ...

Preclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer’s disease Agreement follows more than one ...

Lexington, Massachusetts Tuesday, July 22, 2025, 18:00 Hrs [IST] ...

Repetitive reaching tasks in mature female rats triggered persistent pain-like and sickness behaviors linked to a surge in IL ...